New number of shares and votes in Isofol
GOTHENBURG, Sweden, July 31, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces new number of shares and votes […]
Corporate Action
Isofol’s rights issue fully subscribed – exercises overallotment for Japanese partner
GOTHENBURG, Sweden, 4 July 2025 – Isofol Medical AB (“Isofol” or the “Company”) today announces the outcome of the Company’s
Isofol publishes prospectus in connection with the company’s rights issue
GOTHENBURG, Sweden, 17 June 2025 – The Board of Directors of Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (”Isofol” or
Isofol announces final terms of the rights issue and the potential overallotment issue
GOTHENBURG, Sweden, 5 June 2025 – The Board of Directors of Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (“Isofol” or
The Board of Directors of Isofol resolves on a fully guaranteed Rights Issue of units amounting to approximately SEK 85 million and proposes an over-allotment issue of approximately SEK 10 million
GOTHENBURG, Sweden, 12 May 2025 – The Board of Directors of Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (“Isofol” or
Isofol’s Japanese partner Solasia intensifies its commitment to the clinical development of arfolitixorin
GOTHENBURG, Sweden, March 19, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol”), today announces that the company’s collaboration
Isofol presents a clinical development plan for arfolitixorin
GOTHENBURG, Sweden, March 19, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol”), today presents the company’s continued strategy
Isofol’s board of directors announces its position on minority shareholder’s proposal ahead of extraordinary general meeting
GOTHENBURG, Sweden, December 13, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announces today that all of the company’s
Isofol Medical AB (publ) publishes prospectus and new financial information in connection with listing on Nasdaq Stockholm
GOTHENBURG, Sweden, October 18, 2021 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), (“Isofol” or the
Isofol raises SEK 500 million in oversubscribed rights issue and exercised over-allotment option
GOTHENBURG, Sweden, June 14, 2021 – Isofol Medical AB (publ) (Nasdaq First North Premier Growth Market: ISOFOL) (“Isofol” or the